WASHINGTON, D.C. — The Federal Trade Commission is urging a federal appeals court to reject Amgen Inc.’s argument that its acquisition of patent rights protecting the arthritis drug Enbrel is …

The Federal Trade Commission is urging a federal appeals court to preserve antitrust scrutiny of Amgen Inc.’s acquisition of patent rights connected to

Amgen stock is trading close to a fresh 52-week high while management’s FY 2026 EPS guidance of 22.3

Osmosis Investment Management UK Ltd lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 29.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,649 shares of the medical research company

OMERS ADMINISTRATION Corp lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,717 shares of the medical research company

Ieq Capital LLC cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 47.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,567 shares of the medical research company

Cibc World Market Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 13.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,685 shares of the medical research compan

Allstate Corp reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 52,252 shares of the medical research company

Arete Wealth Advisors LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,923 shares of the medical research company

Amgen stock is holding above $430, supported by its Dow Jones Industrial Average membership and a co

Elevation Point Wealth Partners LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 18.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,505 shares of the medical research company

Beutel Goodman & Co Ltd. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 19.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 520,577 shares of the medical research company

Commerce Bank lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 256,448 shares of the medical research company

Bank of Nova Scotia cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 50.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 156,088 shares of the medical research company